[go: up one dir, main page]

WO2011118929A3 - Novel crystal forms of epirubicin hydrochloride - Google Patents

Novel crystal forms of epirubicin hydrochloride Download PDF

Info

Publication number
WO2011118929A3
WO2011118929A3 PCT/KR2011/001706 KR2011001706W WO2011118929A3 WO 2011118929 A3 WO2011118929 A3 WO 2011118929A3 KR 2011001706 W KR2011001706 W KR 2011001706W WO 2011118929 A3 WO2011118929 A3 WO 2011118929A3
Authority
WO
WIPO (PCT)
Prior art keywords
epirubicin hydrochloride
novel crystal
crystal forms
crystal form
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2011/001706
Other languages
French (fr)
Other versions
WO2011118929A2 (en
Inventor
Moon-Sung Kim
Soon-Hoe Kim
Jun-Ho Choi
Si-Young Sung
Hong-Gyu Lim
Dae-Won Cha
Byoung-Hwa Son
Ki-Moon Ryu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong A Pharmaceutical Co Ltd
Original Assignee
Dong A Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44673730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011118929(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dong A Pharmaceutical Co Ltd filed Critical Dong A Pharmaceutical Co Ltd
Publication of WO2011118929A2 publication Critical patent/WO2011118929A2/en
Publication of WO2011118929A3 publication Critical patent/WO2011118929A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The present invention relates to the crystal form of Epirubicin hydrochloride stable against heat and water and the preparation method thereof. The novel crystal form has the physiochemical property stable against heat and water according to the present invention and it improves the excellent stability of the agents by preventing the relative substances from the one containing it. Furthermore, the crystal form of Epirubicin hydrochloride is suitable for mass production since it is easily prepared.
PCT/KR2011/001706 2010-03-24 2011-03-11 Novel crystal forms of epirubicin hydrochloride Ceased WO2011118929A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100026484A KR101125460B1 (en) 2010-03-24 2010-03-24 Novel Crystal Forms of Epirubicin hydrochloride
KR10-2010-0026484 2010-03-24

Publications (2)

Publication Number Publication Date
WO2011118929A2 WO2011118929A2 (en) 2011-09-29
WO2011118929A3 true WO2011118929A3 (en) 2012-01-05

Family

ID=44673730

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001706 Ceased WO2011118929A2 (en) 2010-03-24 2011-03-11 Novel crystal forms of epirubicin hydrochloride

Country Status (3)

Country Link
KR (1) KR101125460B1 (en)
TW (1) TW201143777A (en)
WO (1) WO2011118929A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102011103751A1 (en) * 2011-05-31 2012-12-06 Heraeus Precious Metals Gmbh & Co. Kg Crystallization of epirubicin hydrochloride
EP2778171A1 (en) * 2013-03-15 2014-09-17 Synbias Pharma Ltd. Crystalline monohydrate of epirubicin hydrochloride
CN109384822B (en) * 2017-08-11 2021-08-03 鲁南制药集团股份有限公司 A kind of epirubicin hydrochloride crystal form and preparation method thereof
KR102275454B1 (en) 2020-05-07 2021-07-09 건국대학교 산학협력단 A Method for Differentiation of Mesenchymal Stem Cells from Pluripotent Stem Cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345068A (en) * 1979-11-22 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process
US5874550A (en) * 1996-12-16 1999-02-23 Pharmachemie B.V. Process for preparing epirubicin or acid addition salts thereof from daunorubicin
US20060063726A1 (en) * 2003-07-02 2006-03-23 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride and method of making the same
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4345068A (en) * 1979-11-22 1982-08-17 Farmitalia Carlo Erba S.P.A. Process for the preparation of 4'-epidaunorubicin, 3',4'-diepidaunorubicin, their doxorubicin analogs, and intermediates used in said process
US5874550A (en) * 1996-12-16 1999-02-23 Pharmachemie B.V. Process for preparing epirubicin or acid addition salts thereof from daunorubicin
US20060063726A1 (en) * 2003-07-02 2006-03-23 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride and method of making the same
US20090099346A1 (en) * 2003-07-02 2009-04-16 Victor Matvienko Thermally stable crystalline epirubicin hydrochloride

Also Published As

Publication number Publication date
KR101125460B1 (en) 2012-03-28
KR20110107237A (en) 2011-09-30
WO2011118929A2 (en) 2011-09-29
TW201143777A (en) 2011-12-16

Similar Documents

Publication Publication Date Title
WO2011133876A3 (en) Oligonucleotides comprising acyclic and abasic nucleosides and analogs
WO2011098582A3 (en) Novel crystalline forms of ivabradine hydrochloride
WO2014014835A3 (en) Criystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
WO2012135025A3 (en) Conjugated lipomers and uses thereof
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
WO2012042371A3 (en) Pharmaceutical composition
WO2009114181A3 (en) Substituted heterocycle fused gamma-carbolines solid
WO2012136383A3 (en) Preparation of sitagliptin intermediates
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2012156998A3 (en) Amorphous mirabegron and processes for crystal forms of mirabegron
WO2010151541A8 (en) Polymorphic form d of bazedoxifene acetate and methods of preparing same
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2010102778A3 (en) Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
WO2011132051A3 (en) Tricycle compounds as phosphodiesterase-10 inhibitors
CA2818986A1 (en) Indole derivatives as modulators of s1p receptors
WO2009053446A3 (en) Pregabalin intermediates and process for preparing them and pregabalin
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2009146202A3 (en) Transketalized compositions, synthesis, and applications
HK1199896A1 (en) Novel compositions for producing cast polyamides
WO2012131707A3 (en) Crystalline form of bortezomib, preparation method and pharmaceutical composition there f
WO2010129636A3 (en) Lenalidomide polymorph
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
EA201001870A1 (en) NEW CRYSTAL SHAPES OF SODIUM CRUST TUNE
WO2011118929A3 (en) Novel crystal forms of epirubicin hydrochloride
WO2011008666A3 (en) 3-phenoxymethylpyrrolidine compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11759678

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11759678

Country of ref document: EP

Kind code of ref document: A2